Niraparib, ALKBH1, and TM4SF1 Interaction Data for BRCA Wild-Type Ovarian Cancer

A 15.6 KB DOCX file contains a research article describing the antitumor mechanism of niraparib in BRCA wild-type ovarian cancer. The study, authored by Po-Wu Liu and published on figshare under CC-BY-4.0, investigates how niraparib promotes ferroptosis by inhibiting TM4SF1 expression via ALKBH1-mediated 6mA DNA modification. The document was last updated on June 1, 2026.

Use Cases

• Study the epigenetic regulation of TM4SF1 expression based on the described ALKBH1-mediated 6mA modification mechanism.
• Investigate the role of ferroptosis in cancer treatment based on the described measurements of Fe2+ and lipid ROS levels.
• Analyze the antitumor effects of niraparib in BRCA wild-type ovarian cancer models based on the described in vitro and in vivo assays.
• Explore biomarker discovery for ovarian cancer treatment response based on the described relationship between TM4SF1 expression and tumor growth.

Strengths

• The dataset is published under the permissive CC-BY-4.0 license, allowing for broad reuse.
• The description provides a detailed methodological overview of the experimental assays used, including 6mA-IP-seq and xenograft models.

Limitations

• The dataset is a 15.6 KB DOCX file, indicating a very limited scope, likely a single research article or summary table.
• Row count and column-level documentation are absent, requiring manual inspection after download to understand data structure.
• The description metadata is limited to the research abstract; actual data quality and format require verification.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from molecular biology assays described in the research article.

Freshness

Last updated 2026-06-01 07:43:58; freshness should be verified.